• PhD Student receives Top Award for Lung Condition Studies.
    Holly Keir (Credit University of Dundee
  • James Chalmers (Credit: University of Dundee)

News & Views

PhD Student receives Top Award for Lung Condition Studies.

Mar 22 2021

University of Dundee, PhD student Holly Keir, who has spent the past year working on potential treatments for COVID-19, has been named as one of the best young scientists in her field and has been presented with the British Thoracic Society’s Early Career Investigator Award at the organisation’s annual Winter Meeting. Holly, based at the University’s School of Medicine, was named the winner of the prestigious prize after delivering a presentation on her research into the severe inflammatory lung condition, bronchiectasis.

Holly led studies that showed for the first time that an excessive type of immune response called neutrophil extracellular trap formation (NETs) was present in bronchiectasis and that this is linked to worsening symptoms. She also showed that antibiotic treatment can reduce NET levels in lungs, leading to improved outcomes for patients.

“I am absolutely delighted to have won this award and I can’t really believe it, to be honest,” she said. “It is so rewarding to have the work you give so much to, recognised in this way.

“The immune system normally tries to clear infections such as viruses or bacteria from the lungs without damaging the lung tissue around them. Our research has shown how this goes wrong in lung conditions. When this happens, white blood cells called neutrophils explode, forming NETs that damage the lungs.”

Holly (27) graduated from Dundee in 2016 with a degree in Biological Sciences, before working as a technician and then starting a PhD the following year in the laboratory of Professor James Chalmers, one of the UK’s foremost lung experts.

Holly’s work on NETs was a key factor in setting up STOP-COVID, a major UK-wide clinical trial of a drug it is hoped may help to prevent the worst ravages of the disease by blocking NETs. She is co-lead of the lab team examining how the drug, Brensocatib, affects the immune system in patients with COVID-19.

Previous trials of Brensocatib have demonstrated that its anti-inflammatory approach has the potential to treat the debilitating cycle of inflammation, infection and damage in lung disease.

“Showing how the immune system goes wrong is the key to unlocking new treatments, both for chronic lung conditions and perhaps also for COVID-19,” she continued. “It has been intense working on STOP-COVID as well as carrying out my PhD work, but it has been an invaluable experience professionally and I am glad to have been able to play some part in the battle against Covid.”

Published in The Lancet Respiratory Medicine.

Digital Edition

International Labmate Buyers' Guide 2021

June 2021

In This Edition Articles - NMR for Electrolyte Design - Specialty Chromatography Detectors: Make or Buy? - Energy Efficient Autoclaves - Misconceptions and Misunderstanding Mass Spectrom...

View all digital editions


M&M 2021

Aug 01 2021 Virtual event

DXC 2021

Aug 02 2021 Virtual event

InformEx Zone at CPhl North America

Aug 10 2021 Pennsylvania, PA, USA & Online


Aug 18 2021 Beijing, China

DioXin 2021

Aug 22 2021 Xi'an, China

View all events